Produção de próteses cranianas tem custo mais baixo
http://portal.anvisa.gov.br/web/guest/rss/-/asset_publisher/Zk4q6UQCj9Pn/content/id/3832523
http://portal.anvisa.gov.br/web/guest/rss/-/asset_publisher/Zk4q6UQCj9Pn/content/id/3832523
http://portal.anvisa.gov.br/web/guest/rss/-/asset_publisher/Zk4q6UQCj9Pn/content/id/3832376
http://portal.anvisa.gov.br/web/guest/rss/-/asset_publisher/Zk4q6UQCj9Pn/content/id/3831732
http://portal.anvisa.gov.br/web/guest/rss/-/asset_publisher/Zk4q6UQCj9Pn/content/id/3831250
http://portal.anvisa.gov.br/web/guest/rss/-/asset_publisher/Zk4q6UQCj9Pn/content/id/3831053
The draft document of ‘WHO Questions and Answers: Similar Biotherapeutic Products’ is available at WHO biological website (http://www.who.int/biologicals/en/). WHO is requesting a feedback from a broad audience of regulators, manufacturers, and other experts. The document is going to be exposed to the public by 23 Feb 2018.
You could download the document directly by clicking on the following link:
http://www.who.int/biologicals/QA_for_SBPs_HK_12_Dec_2017_(2).pdf?ua=1.
In order to provide your comments, please use the template, http://www.who.int/entity/biologicals/WHO_QA_Comment_Form_WHO_QA_30_Nov_2017.doc?ua=1.
If you prefer, you could also use the draft document and comment form attached in this email.
In case that you need any other information, please contact Dr HyeNa KANG (Scientist, Technologies Standards and Norms (Team),Essential Medicines and Health Products (Department), WHO) by kangh@who.int.
http://portal.anvisa.gov.br/web/guest/rss/-/asset_publisher/Zk4q6UQCj9Pn/content/id/3828294
http://portal.anvisa.gov.br/web/guest/rss/-/asset_publisher/Zk4q6UQCj9Pn/content/id/3828257
http://portal.anvisa.gov.br/web/guest/rss/-/asset_publisher/Zk4q6UQCj9Pn/content/id/3828051